Challenge of surrogate endpoints

Southern Medical Journal

Volumn 105, Issue 3, 2012, Pages 156-160

  Furgerson, James L ^a   Hannah, William N ^a   Thompson, Jennifer C ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

biomarkers; clinical endpoint; intermediate endpoint; surrogate endpoint

Indexed keywords

BIOLOGICAL MARKER; ENCAINIDE; EZETIMIBE; FLECAINIDE; FOLIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PLACEBO; VITAMIN B GROUP;

ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CONGESTIVE HEART FAILURE; COST CONTROL; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH CARE PLANNING; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

BIOLOGICAL MARKERS; DATA COLLECTION; DISEASE PROGRESSION; HUMANS; RESEARCH DESIGN;

EID: 84863422016     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318249891e     Document Type: Review

References (44)

1. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8Y15. (Pubitemid 19043669)
2. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583Y1592. (Pubitemid 33126837)
3. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512Y3517. (Pubitemid 39612564)
4. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245Y1255. (Pubitemid 17208898)
5. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109Y2122. (Pubitemid 350146106)
6. Tardif JC, Heinonen T, Orloff D, et al. Vascular biomarkers and surrogates in cardiovascular disease. Circulation 2006;113:2936Y2942. (Pubitemid 44297235)
7. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321:406Y412.
8. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358: 1431Y1443. (Pubitemid 351482735)
9. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008;118:2515Y2522.
10. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468Y1475.
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89Y95.
12. Boissel JP, Collet JP, Moleur P, et al. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992;43:235Y244.
13. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545Y2559.
14. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560Y2572. (Pubitemid 351831357)
15. Pratt CM, Francis MJ, Luck JC, et al. Analysis of ambulatory electrocardiograms in 15 patients during spontaneous ventricular fibrillation with special reference to preceding arrhythmic events. J Am Coll Cardiol 1983;2:789Y797. (Pubitemid 14227252)
16. Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation 1971;44:130Y142.
17. Camm AJ. Cardiac electrophysiology of four new antiarrhythmic drugsV encainide, flecainide, lorcainide and tocainide. Eur Heart J 1984;5(suppl B): 75Y79. (Pubitemid 14011234)
18. Wallace AA, Stupienski RF 3rd, Kothstein T, et al. Demonstration of proarrhythmic activity with the class IC antiarrhythmic agent encainide in a canine model of previous myocardial infarction. J Cardiovasc Pharmacol 1993;21:397Y404. (Pubitemid 23062953)
19. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049Y1057.
20. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775Y1781.
21. Antoniades C, Antonopoulos AS, Tousoulis D, et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 2009;30:6Y15.
22. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99: 178Y182. (Pubitemid 29035977)
23. Willems FF, Aengevaeren WR, Boers GH, et al. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 2002;40:766Y772. (Pubitemid 34925625)
24. Moens AL, Vrints CJ, Claeys MJ, et al. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am J Physiol Heart Circ Physiol 2008;294:H1971YH1977.
25. Ward M, McNulty H, McPartlin J, et al. Plasma homocysteine, a risk factor for cardiovascular disease, is lowered by physiological doses of folic acid. Q J Med 1997;90:519Y524. (Pubitemid 27379816)
26. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578Y1588.
27. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567Y1577.
28. House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010;303:1603Y1609.
29. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979;90:85Y91. (Pubitemid 9096758)
30. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823Y2828. (Pubitemid 17178359)
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7Y22.
32. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477Y1486. (Pubitemid 47572633)
33. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383Y1389.
34. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
35. US Food and Drug Administration. NME drug and new biologic approvals in 2002. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm081683.htm. Published December 31, 2002. Accessed January 3, 2012.
36. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359: 1343Y1356.
37. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605Y613. (Pubitemid 28502636)
38. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321Y333. (Pubitemid 34761611)
39. Mitka M. Amid lingering questions, FDA reprieves LDL cholesterollowering medication. JAMA 2009;301:813Y815.
40. Duivenvoorden R, de Groot E, Stroes ES, et al. Surrogate markers in clinical trialsVchallenges and opportunities. Atherosclerosis 2009;206:8Y16.
41. von Birgelen C, Hartmann M, Mintz GS, et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 2004;110:1579Y1585. (Pubitemid 39297979)
42. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459Y467. (Pubitemid 46184197)
43. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001;104:249Y252. (Pubitemid 32666942)
44. Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by highresolution noninvasive magnetic resonance imaging. Circulation 2002; 106:2884Y2887. (Pubitemid 35424736)